Under the terms of the agreement, Mediware shareholders will receive $22.00 in cash for each share of Mediware common stock.

Mediware president and chief executive officer Thomas Mann said the company has sustained consistent revenue and earnings growth over the past five years by focusing on effectively expanding its product portfolios to new areas of care.

"We look forward to continued investments in our products and people, and to working with Thoma Bravo as we expand our leadership role in healthcare technology," Mann added.

The company said transaction, which requires approval from Mediware shareholders, is subject to customary closing conditions including requisite regulatory approvals.